Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Accumulated Expenses (2024 - 2025)

Prelude Therapeutics' Other Accumulated Expenses history spans 2 years, with the latest figure at $965000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 25.16% year-over-year to $965000.0; the TTM value through Dec 2025 reached $965000.0, up 25.16%, while the annual FY2025 figure was $965000.0, 25.16% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $965000.0 at Prelude Therapeutics, roughly flat from $963000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $965000.0 in Q4 2025 and bottomed at $455000.0 in Q2 2024.